• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

ARID1A 通过保护端粒黏合促进基因组稳定性。

ARID1A promotes genomic stability through protecting telomere cohesion.

机构信息

Gene Expression and Regulation Program, The Wistar Institute, Philadelphia, PA, 19104, USA.

Department of Pharmacology, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, 10032, USA.

出版信息

Nat Commun. 2019 Sep 6;10(1):4067. doi: 10.1038/s41467-019-12037-4.

DOI:10.1038/s41467-019-12037-4
PMID:31492885
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6731242/
Abstract

ARID1A inactivation causes mitotic defects. Paradoxically, cancers with high ARID1A mutation rates typically lack copy number alterations (CNAs). Here, we show that ARID1A inactivation causes defects in telomere cohesion, which selectively eliminates gross chromosome aberrations during mitosis. ARID1A promotes the expression of cohesin subunit STAG1 that is specifically required for telomere cohesion. ARID1A inactivation causes telomere damage that can be rescued by STAG1 expression. Colony formation capability of single cells in G/M, but not G phase, is significantly reduced by ARID1A inactivation. This correlates with an increase in apoptosis and a reduction in tumor growth. Compared with ARID1A wild-type tumors, ARID1A-mutated tumors display significantly less CNAs across multiple cancer types. Together, these results show that ARID1A inactivation is selective against gross chromosome aberrations through causing defects in telomere cohesion, which reconciles the long-standing paradox between the role of ARID1A in maintaining mitotic integrity and the lack of genomic instability in ARID1A-mutated cancers.

摘要

ARID1A 失活导致有丝分裂缺陷。矛盾的是,高 ARID1A 突变率的癌症通常缺乏拷贝数改变(CNAs)。在这里,我们表明 ARID1A 失活导致端粒黏合缺陷,这在有丝分裂过程中选择性地消除了巨大染色体畸变。ARID1A 促进着丝粒亚基 STAG1 的表达,而 STAG1 对于端粒黏合是特异性必需的。ARID1A 失活导致端粒损伤,而 STAG1 的表达可以挽救这种损伤。ARID1A 失活后,G/M 期而非 G 期的单细胞集落形成能力显著降低。这与凋亡增加和肿瘤生长减少相关。与 ARID1A 野生型肿瘤相比,ARID1A 突变型肿瘤在多种癌症类型中显示出明显较少的 CNA。综上所述,这些结果表明,ARID1A 失活通过导致端粒黏合缺陷而对巨大染色体畸变具有选择性,这调和了 ARID1A 在维持有丝分裂完整性方面的作用与 ARID1A 突变型癌症中缺乏基因组不稳定性之间的长期悖论。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39f2/6731242/fcd54d436b58/41467_2019_12037_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39f2/6731242/34a586c1bb92/41467_2019_12037_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39f2/6731242/14e8578cb4db/41467_2019_12037_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39f2/6731242/dca8a93b2b10/41467_2019_12037_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39f2/6731242/362f10ca27ea/41467_2019_12037_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39f2/6731242/60fb19683f4f/41467_2019_12037_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39f2/6731242/fcd54d436b58/41467_2019_12037_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39f2/6731242/34a586c1bb92/41467_2019_12037_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39f2/6731242/14e8578cb4db/41467_2019_12037_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39f2/6731242/dca8a93b2b10/41467_2019_12037_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39f2/6731242/362f10ca27ea/41467_2019_12037_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39f2/6731242/60fb19683f4f/41467_2019_12037_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39f2/6731242/fcd54d436b58/41467_2019_12037_Fig6_HTML.jpg

相似文献

1
ARID1A promotes genomic stability through protecting telomere cohesion.ARID1A 通过保护端粒黏合促进基因组稳定性。
Nat Commun. 2019 Sep 6;10(1):4067. doi: 10.1038/s41467-019-12037-4.
2
mutation and genomic stability.突变与基因组稳定性。
Mol Cell Oncol. 2020 Feb 23;7(3):1690923. doi: 10.1080/23723556.2019.1690923. eCollection 2020.
3
SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells.SWI/SNF 催化亚基的开关驱动 ARID1A 突变细胞对 EZH2 抑制剂的耐药性。
Nat Commun. 2018 Oct 8;9(1):4116. doi: 10.1038/s41467-018-06656-6.
4
ARID1A-mutated ovarian cancers depend on HDAC6 activity.ARID1A基因发生突变的卵巢癌依赖于HDAC6的活性。
Nat Cell Biol. 2017 Aug;19(8):962-973. doi: 10.1038/ncb3582. Epub 2017 Jul 24.
5
Differential regulation of telomere and centromere cohesion by the Scc3 homologues SA1 and SA2, respectively, in human cells.在人类细胞中,Scc3 同源物 SA1 和 SA2 分别对端粒和着丝粒的黏连进行差异调控。
J Cell Biol. 2009 Oct 19;187(2):165-73. doi: 10.1083/jcb.200903096. Epub 2009 Oct 12.
6
Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer.重新利用泛组蛋白去乙酰化酶抑制剂治疗 ARID1A 突变型卵巢癌。
Cell Rep. 2018 Mar 27;22(13):3393-3400. doi: 10.1016/j.celrep.2018.03.019.
7
Cancer-associated mutations in the condensin II subunit CAPH2 cause genomic instability through telomere dysfunction and anaphase chromosome bridges.CAPH2 卷曲螺旋结构域蛋白 2 亚基中的癌症相关突变通过端粒功能障碍和后期染色体桥导致基因组不稳定性。
J Cell Physiol. 2021 May;236(5):3579-3598. doi: 10.1002/jcp.30113. Epub 2020 Oct 20.
8
A kinase-dependent role for Haspin in antagonizing Wapl and protecting mitotic centromere cohesion.组蛋白 Haspin 通过激酶依赖性拮抗 Wapl 来保护有丝分裂着丝粒的黏合。
EMBO Rep. 2018 Jan;19(1):43-56. doi: 10.15252/embr.201744737. Epub 2017 Nov 14.
9
Inactivating ARID1A Tumor Suppressor Enhances TERT Transcription and Maintains Telomere Length in Cancer Cells.使ARID1A肿瘤抑制因子失活可增强端粒酶逆转录酶(TERT)转录并维持癌细胞中的端粒长度。
J Biol Chem. 2016 Apr 29;291(18):9690-9. doi: 10.1074/jbc.M115.707612. Epub 2016 Mar 7.
10
ARID1A ablation leads to multiple drug resistance in ovarian cancer via transcriptional activation of MRP2.ARID1A 缺失通过转录激活 MRP2 导致卵巢癌多药耐药。
Cancer Lett. 2018 Jul 28;427:9-17. doi: 10.1016/j.canlet.2018.04.013. Epub 2018 Apr 13.

引用本文的文献

1
N-Degron-Based PROTAC Targeting PLK1: A Potential Therapeutic Strategy for Cervical Cancer.基于N-端规则靶向PLK1的PROTAC:一种宫颈癌潜在的治疗策略。
Pharmaceutics. 2025 Aug 7;17(8):1027. doi: 10.3390/pharmaceutics17081027.
2
CHK1 inhibition increases the therapeutic response to radiotherapy via antitumor immunity in ARID1A-deficient colorectal cancer.在ARID1A缺陷型结直肠癌中,CHK1抑制通过抗肿瘤免疫增强对放疗的治疗反应。
Cell Death Dis. 2025 Aug 1;16(1):584. doi: 10.1038/s41419-025-07912-6.
3
Epigenetic regulators in cancer therapy and progression.

本文引用的文献

1
ARID1A spatially partitions interphase chromosomes.ARID1A 使间期染色体在空间上分隔开。
Sci Adv. 2019 May 22;5(5):eaaw5294. doi: 10.1126/sciadv.aaw5294. eCollection 2019 May.
2
SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells.SWI/SNF 催化亚基的开关驱动 ARID1A 突变细胞对 EZH2 抑制剂的耐药性。
Nat Commun. 2018 Oct 8;9(1):4116. doi: 10.1038/s41467-018-06656-6.
3
Cell Synchronization by Double Thymidine Block.通过双胸腺嘧啶核苷阻滞进行细胞同步化。
癌症治疗与进展中的表观遗传调控因子
NPJ Precis Oncol. 2025 Jun 28;9(1):206. doi: 10.1038/s41698-025-01003-7.
4
Disease, Central Precocious Puberty, and Bone Fragility-A Case Report.疾病、中枢性性早熟与骨脆性——一例报告
Diagnostics (Basel). 2025 Apr 24;15(9):1076. doi: 10.3390/diagnostics15091076.
5
Advances in the study of the role of high-frequency mutant subunits of the SWI/SNF complex in tumors.SWI/SNF复合物高频突变亚基在肿瘤中作用的研究进展
Front Oncol. 2024 Dec 4;14:1463892. doi: 10.3389/fonc.2024.1463892. eCollection 2024.
6
R-loops' m6A modification and its roles in cancers.R 环的 m6A 修饰及其在癌症中的作用。
Mol Cancer. 2024 Oct 18;23(1):232. doi: 10.1186/s12943-024-02148-y.
7
Aberrant SWI/SNF Complex Members Are Predominant in Rare Ovarian Malignancies-Therapeutic Vulnerabilities in Treatment-Resistant Subtypes.异常的SWI/SNF复合物成员在罕见卵巢恶性肿瘤中占主导地位——耐药亚型中的治疗脆弱性。
Cancers (Basel). 2024 Sep 3;16(17):3068. doi: 10.3390/cancers16173068.
8
Genome-Wide CRISPR Screen Identifies KEAP1 Perturbation as a Vulnerability of ARID1A-Deficient Cells.全基因组CRISPR筛选确定KEAP1扰动是ARID1A缺陷细胞的一个脆弱点。
Cancers (Basel). 2024 Aug 24;16(17):2949. doi: 10.3390/cancers16172949.
9
Circulating tumor cells: from new biological insights to clinical practice.循环肿瘤细胞:从新的生物学见解到临床实践。
Signal Transduct Target Ther. 2024 Sep 2;9(1):226. doi: 10.1038/s41392-024-01938-6.
10
Increased genomic instability and reshaping of tissue microenvironment underlie oncogenic properties of mutations.突变的致癌特性源于基因组不稳定性的增加和组织微环境的重塑。
Sci Adv. 2024 Mar 15;10(11):eadh4435. doi: 10.1126/sciadv.adh4435.
Bio Protoc. 2018 Sep 5;8(17). doi: 10.21769/BioProtoc.2994.
4
SWI/SNF Complexes in Ovarian Cancer: Mechanistic Insights and Therapeutic Implications.SWI/SNF 复合物在卵巢癌中的作用:机制见解与治疗意义。
Mol Cancer Res. 2018 Dec;16(12):1819-1825. doi: 10.1158/1541-7786.MCR-18-0368. Epub 2018 Jul 23.
5
Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer.膀胱癌患者来源类器官模型中的肿瘤进化和药物反应。
Cell. 2018 Apr 5;173(2):515-528.e17. doi: 10.1016/j.cell.2018.03.017.
6
Comprehensive Characterization of Cancer Driver Genes and Mutations.全面描绘癌症驱动基因和突变。
Cell. 2018 Apr 5;173(2):371-385.e18. doi: 10.1016/j.cell.2018.02.060.
7
Establishing and dissolving cohesion during the vertebrate cell cycle.建立和解除脊椎动物细胞周期中的黏着。
Curr Opin Cell Biol. 2018 Jun;52:51-57. doi: 10.1016/j.ceb.2018.01.010. Epub 2018 Feb 10.
8
High-level expression of ARID1A predicts a favourable outcome in triple-negative breast cancer patients receiving paclitaxel-based chemotherapy.ARID1A 的高表达预示着接受紫杉醇为基础的化疗的三阴性乳腺癌患者有良好的预后。
J Cell Mol Med. 2018 Apr;22(4):2458-2468. doi: 10.1111/jcmm.13551. Epub 2018 Feb 1.
9
BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer.BET 溴结构域抑制与聚腺苷二磷酸核糖聚合酶抑制剂在卵巢上皮性癌中具有协同作用。
Cell Rep. 2017 Dec 19;21(12):3398-3405. doi: 10.1016/j.celrep.2017.11.095.
10
Nucleases Acting at Stalled Forks: How to Reboot the Replication Program with a Few Shortcuts.在停滞叉处起作用的核酸酶:如何通过一些快捷方式重新启动复制程序。
Annu Rev Genet. 2017 Nov 27;51:477-499. doi: 10.1146/annurev-genet-120116-024745.